These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 31245497)

  • 1. Experience of contamination during autologous cell manufacturing in cell processing facility under the Japanese Medical Practitioners Act and the Medical Care Act.
    Mizutani M; Samejima H; Terunuma H; Kino-Oka M
    Regen Ther; 2016 Dec; 5():25-30. PubMed ID: 31245497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variation in the manufacturing reproducibility of autologous cell-based products depending on raw material shipment conditions.
    Mizutani M; Terunuma H; Samejima H; Ashiba K; Kino-Oka M
    Regen Ther; 2019 Dec; 12():102-107. PubMed ID: 31890773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel, flexible and automated manufacturing facility for cell-based health care products: Tissue Factory.
    Kikuchi T; Kino-Oka M; Wada M; Kobayashi T; Kato M; Takeda S; Kubo H; Ogawa T; Sunayama H; Tanimoto K; Mizutani M; Shimizu T; Okano T
    Regen Ther; 2018 Dec; 9():89-99. PubMed ID: 30525079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Basic points to consider regarding the preparation of extracellular vesicles and their clinical applications in Japan.
    Tsuchiya A; Terai S; Horiguchi I; Homma Y; Saito A; Nakamura N; Sato Y; Ochiya T; Kino-Oka M;
    Regen Ther; 2022 Dec; 21():19-24. PubMed ID: 35619946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell/tissue processing information system for regenerative medicine.
    Iwayama D; Yamato M; Tsubokura T; Takahashi M; Okano T
    J Tissue Eng Regen Med; 2016 Nov; 10(11):908-915. PubMed ID: 24700532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biopharmaceutical Industry Approaches to Facility Segregation for Viral Safety: An Effort from the Consortium on Adventitious Agent Contamination in Biomanufacturing.
    Barone PW; Avgerinos S; Ballard R; Brussel A; Clark P; Dowd C; Gerentes L; Hart I; Keumurian FJ; Kindermann J; Leung JC; Ly N; Mink S; Minning S; Mullberg J; Murphy M; Nöske K; Parriott S; Shum B; Wiebe ME; Springs SL
    PDA J Pharm Sci Technol; 2019; 73(2):191-203. PubMed ID: 30361281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A QRM Discussion of Microbial Contamination of Non-sterile Drug Products, Using FDA and EMA Warning Letters Recorded between 2008 and 2016.
    Santos AMC; Doria MS; Meirinhos-Soares L; Almeida AJ; Menezes JC
    PDA J Pharm Sci Technol; 2018; 72(1):62-72. PubMed ID: 29242394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-contamination risk and decontamination during changeover after cell-product processing.
    Mizuno M; Yori K; Takeuchi T; Yamaguchi T; Watanabe K; Tomaru Y; Shimizu N; Sekiya I
    Regen Ther; 2023 Mar; 22():30-38. PubMed ID: 36618490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Robotics and Aseptic Processing in View of Regulatory Requirements.
    Tanzini A; Ruggeri M; Bianchi E; Valentino C; Vigani B; Ferrari F; Rossi S; Giberti H; Sandri G
    Pharmaceutics; 2023 May; 15(6):. PubMed ID: 37376030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MIT CAACB Risk Assessment Case Study: Assessing Virus Cross-Contamination Risk between Two Simultaneous Processes in an Open Biomanufacturing Facility.
    Koenigsberg AL; Fowler V; Domike R; Brussel A; Barone PW; Keumurian FJ; Leung J; Wiebe ME; Brewer MT; Chan S; Dumey N; Fournillier A; Goodnight M; Kindermann J; Leavy R; Lee B; Minning S; Murphy M; Myers E; Nahabedian A; Nanda K; Parriott S; Raju GK; Scallan C; Schoch S; Shiminsky J; Shum B; Teitz S; Westrek B; Springs SL
    PDA J Pharm Sci Technol; 2023; 77(2):115-132. PubMed ID: 36241212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GMP-Compliant Production of Autologous Adipose-Derived Stromal Cells in the NANT 001 Closed Automated Bioreactor.
    Fitzgerald JC; Duffy N; Cattaruzzi G; Vitrani F; Paulitti A; Mazzarol F; Mauro P; Sfiligoj A; Curcio F; Jones DM; McInerney V; Krawczyk J; Kelly J; Finnerty A; McDonagh K; McCabe U; Duggan M; Connolly L; Shaw G; Murphy M; Barry F
    Front Bioeng Biotechnol; 2022; 10():834267. PubMed ID: 35356775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Case Study: A Novel Bacterial Contamination in Cell Culture Production--Leptospira licerasiae.
    Chen J; Bergevin J; Kiss R; Walker G; Battistoni T; Lufburrow P; Lam H; Vinther A
    PDA J Pharm Sci Technol; 2012; 66(6):580-91. PubMed ID: 23183653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Remote audit practice for inspection of structural and equipment standards for cell processing facilities under the act on the safety of regenerative medicine in Japan.
    Sasai M; Okamoto M; Tanigawa S; Okada S; Sugiyama D; Myoui A
    Regen Ther; 2024 Mar; 25():85-91. PubMed ID: 38187516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality Control Testing for Tracking Endotoxin-Producing Gram-Negative Bacteria during the Preparation of Polyvalent Snake Antivenom Immunoglobulin.
    Sheraba NS; Diab MR; Yassin AS; Amin MA; Zedan HH
    PDA J Pharm Sci Technol; 2015; 69(4):499-510. PubMed ID: 26242786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Qualification of academic facilities for small-scale automated manufacture of autologous cell-based products.
    Hourd P; Chandra A; Alvey D; Ginty P; McCall M; Ratcliffe E; Rayment E; Williams DJ
    Regen Med; 2014; 9(6):799-815. PubMed ID: 25431916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterizing the rapid spread of porcine epidemic diarrhea virus (PEDV) through an animal food manufacturing facility.
    Schumacher LL; Huss AR; Cochrane RA; Stark CR; Woodworth JC; Bai J; Poulsen EG; Chen Q; Main RG; Zhang J; Gauger PC; Ramirez A; Derscheid RJ; Magstadt DM; Dritz SS; Jones CK
    PLoS One; 2017; 12(11):e0187309. PubMed ID: 29095859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A study on ensuring the quality and safety of pharmaceuticals and medical devices derived from processing of autologous human induced pluripotent stem(-like) cells.
    Hayakawa T; Aoi T; Umezawa A; Ozawa K; Sato Y; Sawa Y; Matsuyama A; Yamanaka S; Yamato M
    Regen Ther; 2015 Dec; 2():81-94. PubMed ID: 31245462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of Particles in Parenteral Drug Raw Materials.
    Lee K; Lankers M; Valet O
    PDA J Pharm Sci Technol; 2018; 72(6):599-607. PubMed ID: 29669816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Consideration of and expectations for the Pharmaceuticals, Medical Devices and Other Therapeutic Products Act in Japan.
    Okada K; Koike K; Sawa Y
    Regen Ther; 2015 Jun; 1():80-83. PubMed ID: 31245444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Environmental Monitoring for Closed Robotic Workcells Used in Aseptic Processing: Data to Support Advanced Environmental Monitoring Strategies.
    McCall J; Barnard N; Gadient K; Kasireddy C; Kurtz A; Li Y; Page T; Putnam T; Brennan Á
    AAPS PharmSciTech; 2022 Aug; 23(6):215. PubMed ID: 35922577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.